Pharmacogenomics and the treatment of acute myeloid leukemia

Autores de IIS La Fe

• Juan Eduardo Megías Vericat

  Autor

• Pau Montesinos Fernández

  Autor

• María José Herrero Cervera

  Autor

• Virginia Bosó Ribelles

  Autor

• David Martínez Cuadrón

  Autor

• José Luis Poveda Andrés

  Autor

• Miguel Ángel Sanz Alonso

  Autor

• Salvador F Aliño Pellicer

  Autor

Grupos

• Farmacogenética

• Hematología y Hemoterapia

Abstract

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging genes recently studied in AML, such as DNA repair genes, genes potentially related to chemotherapy response or AML prognosis, have also been included.

Keywords

• acute myeloid leukemia; anthracyclines; cytarabine; effectiveness; polymorphism; SNP; toxicity